CD47 blockade enhances cisplatin sensitivity by inhibiting DNA repair gene expression

• Cisplatin upregulates CD47 via ATM/NF-κB signaling, promoting chemoresistance. • CD47 depletion or blockade sensitizes cancer cells to cisplatin by enhancing DNA damage. • CD47 regulates DNA repair genes ERCC1, FANCA, and BRCA2 through ATM/NF-κB. • Combining CD47-targeted therapy with cisplatin offers a dual strategy to overcome immune evasion and improve efficacy.